Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;11(12):4434-4440.
doi: 10.21037/tcr-22-2873.

Serum diagnostic markers for malignant pleural mesothelioma: a narrative review

Jing-Jing Wang  1 , Li Yan  2
Affiliations
Review

Serum diagnostic markers for malignant pleural mesothelioma: a narrative review

Jing-Jing Wang et al. Transl Cancer Res. 2022 Dec.

Abstract

Background and objective: The prognosis of patients with malignant pleural mesothelioma (MPM) is poor, and early diagnosis is key to improving the prognosis. Pleural biopsy is the gold reference for diagnosing MPM, but it is an invasive method that can cause operation-related complications such as bleeding and infection. Serum biomarkers, with the advantages of mini-invasiveness, short turnaround time and objectiveness, represent a promising diagnostic tool for MPM.

Methods: We searched the PubMed database to identify clinical studies published between 1990 to July 2022 that investigated the diagnostic accuracy of serum biomarkers for MPM. The major findings of the verified studies were summarized.

Key content and findings: Currently, there are many available serum markers for MPM, including mesothelin, soluble mesothelin-related peptides, osteopontin, fibulin-3, high mobility group box 1, and microRNA. Systematic review and meta-analysis evidence indicates that the sensitivity and specificity of these serum markers are less than 0.90. In addition, a large portion of previous studies have limitations, especially the representativeness of the study cohort.

Conclusions: The diagnostic accuracy of currently available serum biomarkers is unsatisfactory, and further studies are needed to investigate novel serum biomarkers.

Keywords: Malignant pleural mesothelioma (MPM); diagnosis; mesothelin; narrative review; osteopontin; serum biomarker.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-2873/coif). The authors have no conflicts of interest to declare.

Similar articles

See all similar articles

Cited by

References

    1. Carbone M, Adusumilli PS, Alexander HR, Jr, et al. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin 2019;69:402-29. 10.3322/caac.21572 - DOI - PMC - PubMed
    1. Schumann SO, Kocher G, Minervini F. Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature. J Thorac Dis 2021;13:2510-23. 10.21037/jtd-20-2761 - DOI - PMC - PubMed
    1. Freudenberger DC, Shah RD. A narrative review of the health disparities associated with malignant pleural mesothelioma. J Thorac Dis 2021;13:3809-15. 10.21037/jtd-20-3516 - DOI - PMC - PubMed
    1. Ossowski S, Hung YY, Banks K, et al. Improving outcomes in malignant pleural mesothelioma in an integrated health care system. J Thorac Dis 2022;14:3352-63. 10.21037/jtd-22-427 - DOI - PMC - PubMed
    1. Woolhouse I, Bishop L, Darlison L, et al. British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. Thorax 2018;73:i1-i30. 10.1136/thoraxjnl-2017-211321 - DOI - PubMed